A Study to Compare the PK , Safety, and Immunogenicity of QL2109 With Daratumumab in Male Subjects

NCT07400744 | Not Yet Recruiting Phase 1

• 1 other identifier: QL2109-102
• Study Type: interventional
• Target: 102
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this clinical study is to establish the comparability of the pharmacokinetics and similarity of the safety and immunogenicity profiles of QL2109 and Darzalex following a single intravenous infusion in healthy male subjects.

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (1)

• AUC0-∞

  Area under the serum concentration-time curve from time 0 to infinity

  Up to Day 71

Study Arms (2)

QL2109

EXPERIMENTAL

Drug: QL2109

Darzalex

ACTIVE COMPARATOR

Drug: Darzalex

Interventions

QL2109 DRUG

Recombinant anti-CD38 fully human monoclonal antibody.

QL2109

Darzalex DRUG

Daratumumab injection

Darzalex

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• The subject should be a voluntary participant who has understood and signed the ICF.
• Age ≥ 18 years and ≤ 50 years, male (including the boundary values).
• Body weight ≥ 55 kilograms (kg), body mass index (BMI) = weight (kg) / height² (m²), with BMI within the range of 18-28 (including the boundary values).
• The subject agrees to use reliable contraceptive measures (such as abstinence, sterilization surgery, oral contraceptives, injectable contraceptives like medroxyprogesterone, or subcutaneous contraceptive implants) for themselves and their partner during the study and for 6 months after the trial drug infusion.
• No history of diseases, or any past medical history abnormalities are deemed clinically insignificant and judged by the study physician to have no impact on the trial.

You may not qualify if:

• Individuals with a history or current diagnosis of any clinically significant disease that may interfere with the trial results, including but not limited to disorders of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric, or metabolic systems, or those with clinically significant allergic reactions or allergic predisposition, angioedema, interstitial pneumonia, or acute respiratory distress syndrome.
• Individuals with acute, chronic, or potential infectious diseases within 1 month prior to dosing.
• Individuals with known immune system disorders (autoimmune diseases or immunodeficiency diseases), including but not limited to autoimmune hemolytic anemia.
• Individuals with ocular diseases, including a history of intraocular surgery or laser eye surgery.
• Individuals with a history of localized cutaneous herpes zoster within 6 months prior to dosing.
• Individuals with disseminated cutaneous herpes zoster or herpes zoster involving the central nervous system, either currently or historically.
• Individuals with a positive blood group antibody screening (indirect antiglobulin test).
• Individuals who have used monoclonal antibodies, cell therapies, or similar treatments within 6 months prior to dosing, or have previously received daratumumab or its analogues, or drugs targeting CD38.
• Individuals who have taken any medications (except premedication for QL2109 injection/DARZALEX®) within 2 weeks prior to dosing, including prescription drugs, over-the-counter drugs, and herbal medicines.
• Individuals with a history of drug or food allergies, including allergies to any drug or excipient used in the clinical trial.
• Individuals with a history of needle or blood phobia, or difficulty with venous blood collection (e.g., history of difficult blood draws or symptoms/signs indicating intolerance to venipuncture).
• Individuals who have donated blood or experienced blood loss totaling 200 mL or more within 3 months prior to dosing.
• Individuals who have participated in any other drug or medical device clinical trials within 3 months prior to dosing (or within 5 half-lives of the investigational drug if the half-life exceeds 3 months).
• Individuals who have undergone major surgery within 3 months prior to signing the informed consent form (ICF).
• Individuals who are positive for hepatitis B surface antigen (HBsAg), hepatitis B e antigen (HBeAg), and/or hepatitis B core antibody (HBcAb); positive for hepatitis C virus antibody (HCV); positive for Treponema pallidum antibody; or positive for human immunodeficiency virus (HIV) antibody.

Sponsors & Collaborators

• Qilu Pharmaceutical Co., Ltd.: lead

MeSH Terms

Conditions

Multiple Myeloma

Interventions

daratumumab

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Central Study Contacts

Huan Zhou, Ph.D.

CONTACT

13665527160; zhouhuanbest@vip.163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: RANDOMIZED
• Masking: DOUBLE
• Who Masked: PARTICIPANT, INVESTIGATOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: February 3, 2026
• First Posted: February 10, 2026
• Study Start: March 1, 2026
• Primary Completion (Estimated): September 1, 2026
• Study Completion (Estimated): October 1, 2026
• Last Updated: February 10, 2026

Record last verified: 2026-02